Pulmonary Hypertension - Pipeline Review, H2 2015

Pulmonary Hypertension - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Pulmonary Hypertension - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Actelion Ltd APT Therapeutics, Inc. Arena Pharmaceuticals, Inc. Asahi Kasei Pharma Corp. Ascendis Pharma A/S Bayer AG Bial - Portela & Ca, S.A. Biolab Sanus Farmaceutica Ltda. Cardioxyl Pharmaceuticals, Inc. Carolus Therapeutics, Inc. Celsion Corporation Complexa, Inc. Corridor Pharmaceuticals Inc. Cytokinetics, Inc. Eli Lilly and Company Gilead Sciences, Inc. Hanmi Pharmaceuticals, Co. Ltd. Insmed Incorporated Kowa Company, Ltd. Lacer, S.A. LTT Bio-Pharma Co., Ltd. Mezzion Pharma Co. Ltd. miRagen Therapeutics, Inc. Nippon Shinyaku Co., Ltd. Novartis AG Peloton Therapeutics, Inc. PharmaIN Corporation PhaseBio Pharmaceuticals, Inc. Pluristem Therapeutics Inc. Proteo, Inc. Pulmokine, Inc. Reata Pharmaceuticals, Inc. Respira Therapeutics, Inc. Sagene Pharmaceuticals, Inc. Sanofi Selten Pharma, Inc Serodus ASA Silence Therapeutics Plc Sinoxa Pharma GmbH SteadyMed Therapeutics, Inc. Suda Ltd Toray Industries, Inc. VBS Pharmaceuticals Vectura Group Plc Vicore Pharma AB


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###